# Conjunctival lymphoma: case report

**Authors:** Andreea-Cristina Baltă, Mălina Adriana Mihai, Alexandru Mihai Ionescu, Mădălina Radu, Ioan Chițac, Gabriela Murgoi, Mihail Zemba

PMC · DOI: 10.22336/rjo.2025.69 · 2025-07-01

## TL;DR

This case report details the diagnosis and treatment of a rare conjunctival lymphoma in a 54-year-old woman.

## Contribution

The paper presents a clinical case of extranodal marginal zone B-cell conjunctival lymphoma and its management with brachytherapy.

## Key findings

- The patient was diagnosed with extranodal marginal zone B-cell conjunctival lymphoma via biopsy.
- Radiotherapy with brachytherapy was chosen as the treatment approach due to localized disease.
- Conjunctival lymphoma often presents as a painless salmon-pink lesion and requires biopsy for confirmation.

## Abstract

To report the diagnosis and therapeutic approach in the case of a patient with conjunctival lymphoma.

A 54-year-old caucasian female presented to the hospital with a painless conjunctival mass in the right eye of at least three months duration. The ophthalmological examination showed a “salmon patch” conjunctival lesion in the inferior fornix. An incisional biopsy of the conjunctival lesion was performed, and the histopathological examination confirmed the diagnosis of extranodal marginal zone B-cell conjunctival lymphoma. The CT scan showed no systemic involvement. It was decided to start radiotherapy with brachytherapy.

Conjunctival lymphoma is a rare ocular malignancy arising from polyclonal proliferation of lymphocytes. The most common subtype is extranodal marginal zone B-cell lymphoma (EMZL), followed by diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and T-cell lymphoma (TL). Clinical manifestations are non-specific; they usually present as a unilateral or bilateral painless, salmon-pink conjunctival lesion, often without systemic symptoms. Definite diagnosis requires conjunctival biopsy and relies on histopathology and immunohistochemistry, with molecular profiling playing an increasing role in risk stratification. Treatment strategies include: radiotherapy, immunotherapy (Interferon-α2b, Rituximab), chemotherapy, and antibiotherapy. Prognosis is generally favorable, with high survival rates, especially in localized cases.

Conjunctival lymphoma can be easily overlooked during a routine examination; therefore, a thorough clinical evaluation, advanced imaging, histopathological, and immunohistochemical analysis are essential for appropriate management. Systemic staging and an interdisciplinary approach involving ophthalmology, medical oncology, and radiation oncology are necessary for optimal treatment planning and outcome.

## Linked entities

- **Diseases:** extranodal marginal zone B-cell lymphoma (MONDO:0007650), diffuse large B-cell lymphoma (MONDO:0018905), follicular lymphoma (MONDO:0018906), mantle cell lymphoma (MONDO:0018876), T-cell lymphoma (MONDO:0015760)

## Full-text entities

- **Diseases:** conjunctival lesion (MESH:D003229), DLBCL (MESH:D016403), Conjunctival lymphoma (MESH:D008223), -cell conjunctival lymphoma (MESH:D016399), MCL (MESH:D020522), FL (MESH:D008224), ocular malignancy (MESH:D009369), EMZL (MESH:D018442)
- **Chemicals:** Rituximab (MESH:D000069283)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12580659/full.md

---
Source: https://tomesphere.com/paper/PMC12580659